Feiteng Lu

1.4k total citations
21 papers, 306 citations indexed

About

Feiteng Lu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Feiteng Lu has authored 21 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Feiteng Lu's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Feiteng Lu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Feiteng Lu collaborates with scholars based in China, United States and Germany. Feiteng Lu's co-authors include Fan Luo, Hongyun Zhao, Yan Huang, Jiaxin Cao, Wenjuan Ma, Jianhua Zhan, Ling Yang, Zhang Li, Donald Maxwell Parkin and Sarah Whelan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Letters and Cell Death and Disease.

In The Last Decade

Feiteng Lu

21 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feiteng Lu China 12 118 102 77 63 57 21 306
S.N. Kehlet Denmark 12 114 1.0× 122 1.2× 100 1.3× 59 0.9× 60 1.1× 17 386
D. Viñal Spain 10 88 0.7× 166 1.6× 33 0.4× 45 0.7× 90 1.6× 33 285
Joshua F. Coleman United States 9 96 0.8× 139 1.4× 60 0.8× 44 0.7× 33 0.6× 18 274
Francesca Consoli Italy 9 92 0.8× 209 2.0× 128 1.7× 56 0.9× 72 1.3× 37 367
Zuyi Yang China 10 184 1.6× 119 1.2× 125 1.6× 61 1.0× 167 2.9× 20 350
Kristen K. Ciombor United States 10 84 0.7× 191 1.9× 62 0.8× 18 0.3× 78 1.4× 26 315
Xiangshan Yang China 12 133 1.1× 76 0.7× 72 0.9× 42 0.7× 70 1.2× 21 295
Young-Joo Shin South Korea 10 92 0.8× 65 0.6× 41 0.5× 30 0.5× 40 0.7× 28 349
Shengwei Mo China 11 93 0.8× 217 2.1× 56 0.7× 157 2.5× 50 0.9× 30 348

Countries citing papers authored by Feiteng Lu

Since Specialization
Citations

This map shows the geographic impact of Feiteng Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feiteng Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feiteng Lu more than expected).

Fields of papers citing papers by Feiteng Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feiteng Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feiteng Lu. The network helps show where Feiteng Lu may publish in the future.

Co-authorship network of co-authors of Feiteng Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Feiteng Lu. A scholar is included among the top collaborators of Feiteng Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feiteng Lu. Feiteng Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Qiuyun, Lin Zhang, Wentao Pan, et al.. (2024). APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways. International Immunopharmacology. 139. 112615–112615. 1 indexed citations
2.
Cao, Jiaxin, Qun Chen, Feiteng Lu, et al.. (2024). PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma. Cell Death and Disease. 15(3). 237–237. 1 indexed citations
3.
Lu, Feiteng, Yuen Lam Dora Ng, Cindy H. Chau, et al.. (2024). Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives. Bioorganic & Medicinal Chemistry Letters. 110. 129858–129858. 3 indexed citations
4.
Luo, Fan, Han Li, Wenjuan Ma, et al.. (2023). The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular and Molecular Immunology. 21(1). 60–79. 37 indexed citations
5.
Cao, Jiaxin, Qun Chen, Xue Bai, et al.. (2023). Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors. Annals of Medicine. 55(2). 2280002–2280002. 16 indexed citations
6.
Luo, Fan, Feiteng Lu, Jiaxin Cao, et al.. (2022). HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer. Cancer Letters. 531. 39–56. 57 indexed citations
7.
Cao, Jiaxin, Fan Luo, Wenjuan Ma, et al.. (2022). Predictive Value of High Preoperative Serum Total Protein and Elevated Hematocrit in Patients with Non-Small-Cell Lung Cancer after Radical Resection. Nutrition and Cancer. 74(10). 3533–3545. 2 indexed citations
8.
Chen, Zhigang, Jianhong Peng, Jian Sun, et al.. (2022). Novel prognostic model predicts overall survival in colon cancer based on RNA splicing regulation gene expression. Cancer Science. 113(10). 3330–3346. 4 indexed citations
9.
10.
11.
12.
Luo, Fan, Zhonghan Zhang, Ting Zhou, et al.. (2020). Prognostic value of serum high‐density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery. SHILAP Revista de lepidopterología. 10(2). e94–e94. 3 indexed citations
13.
Wang, Wei, et al.. (2020). The cross‐sectional study of hepatic lipase SNPs and plasma lipid levels. Food Science & Nutrition. 8(2). 1162–1172. 2 indexed citations
14.
Zhao, Ping, Jun Wu, Feiteng Lu, et al.. (2019). The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer. BMC Cancer. 19(1). 201–201. 13 indexed citations
15.
Zhang, Zhonghan, Shen Zhao, Yuanyuan Zhao, et al.. (2019). Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology. 11. 3862506692–3862506692. 12 indexed citations
16.
Zhang, Zhonghan, Yuanyuan Zhao, Feiteng Lu, et al.. (2019). Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Annals of Translational Medicine. 7(18). 452–452. 12 indexed citations
17.
Lu, Feiteng, Shuang Liu, Qing-Yun Hao, et al.. (2018). Association Between Complement Factor C2/C3/CFB/CFH Polymorphisms and Age-Related Macular Degeneration: A Meta-Analysis. Genetic Testing and Molecular Biomarkers. 22(9). 526–540. 26 indexed citations
18.
Lu, Feiteng, et al.. (2018). Dentin dysplasia type I—A dental disease with genetic heterogeneity. Oral Diseases. 25(2). 439–446. 24 indexed citations
19.
20.
Yang, Ling, et al.. (2005). Statistics on cancer in China: cancer registration in 2002. European Journal of Cancer Prevention. 14(4). 329–335. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S.N. Kehlet Breakdown of academic impact, for papers by D. Viñal Breakdown of academic impact, for papers by Joshua F. Coleman Breakdown of academic impact, for papers by Francesca Consoli Breakdown of academic impact, for papers by Zuyi Yang Breakdown of academic impact, for papers by Kristen K. Ciombor Breakdown of academic impact, for papers by Xiangshan Yang Breakdown of academic impact, for papers by Young-Joo Shin Breakdown of academic impact, for papers by Shengwei Mo
Rankless by CCL
2026